Hepatic chemoprotective enzyme responses to 2‐substituted selenazolidine‐4(R)‐carboxylic acids
- 1 November 2006
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 20 (6) , 292-301
Abstract
In epidemiology and human supplementation studies, as well as many animal models, selenium has shown antitumorigenic activity. The mechanism of action, however, has not been satisfactorily resolved. Selenium supplementation affects many enzymes in addition to those where selenocysteine is an essential component. Such enzymes include cytoprotective detoxifying enzymes, and the regulation of these enzymes by a set of 2‐substituted selenazolidine‐4(R)‐carboxylic acids (SCAs) has been investigated. Following seven consecutive daily doses of these prodrugs of L‐selenocysteine, changes in hepatic enzyme activities and/or mRNA levels of glutathione transferase (GST), microsomal epoxide hydrolase (mEH), NAD(P)H‐quinone oxidoreductase (NQO), UDP‐glucuronosyltransferase (UGT), glutathione peroxidase (GPx), and thioredoxin reductase (TR) have been observed. Among the enzymes examined, UGTs and GPx were found to be the least affected. Among the compounds, 2‐oxoSCA produced the most changes and 2‐phenylSCA produced the least, none. For no two compounds was the pattern of changes identical, and for a single compound, few changes were reproduced in common by the two routes of administration investigated. In general, more changes were elicited following intraperitoneal (i.p.) administration than with the intragastric (i.g.) route. This dominance was typified by 2‐butylSCA and 2‐cyclohexylSCA where enzyme activity elevations (TR and mEH with both, NQO with 2‐butylSCA) were seen only with the i.p. route. With 2‐oxoSCA, however, GST, TR, and NQO activities were found to be elevated independent of route. Only with GST (both routes) and TR (i.p. route), elevations in mRNAs accompanied the 2‐oxoSCA elicited elevations of activities at the time of sacrifice. For some enzymes, most notably mEH with compounds administered i.p., elevations in mRNAs were not manifest as increased enzyme activity. Thus, although constituting a closely related series of compounds, each 2‐substituted SCA produced its own unique pattern of changes, and for most members, changes were predominant following i.p. administration. © 2006 Wiley Periodicals, Inc. J Biochem Mol Toxicol 20:292–301, 2006; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jbt.20148Keywords
This publication has 50 references indexed in Scilit:
- Murine hepatoma (Hepa1c1c7) cells: A responsive in vitro system for chemoprotective enzyme induction by organoselenium compoundsToxicology in Vitro, 2006
- Acute effects of novel selenazolidines on murine chemoprotective enzymesChemico-Biological Interactions, 2006
- Cancer chemoprevention: Selenium as a prooxidant, not an antioxidantMedical Hypotheses, 2006
- Molecular chemoprevention by selenium: A genomic approachMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005
- A report of high-dose selenium supplementation: response and toxicitiesJournal of Trace Elements in Medicine and Biology, 2004
- Diverse Effects of Methylseleninic Acid on the Transcriptional Program of Human Prostate Cancer CellsMolecular Biology of the Cell, 2004
- Characteristics of Selenazolidine Prodrugs of Selenocysteine: Toxicity and Glutathione Peroxidase Induction in V79 CellsJournal of Medicinal Chemistry, 2003
- Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer TrialBJU International, 2003
- Drug metabolizing enzyme induction by benzoquinolines, acridine, and quinacrine; Tricyclic aromatic molecules containing a single heterocyclic nitrogenJournal of Biochemical Toxicology, 1996
- Serum vitamin E, serum selenium and the risk of gastrointestinal cancerInternational Journal of Cancer, 1988